Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 6, 2014, Pages 1184-1193

  de Andrade, Ana Valéria Gouveia ^a   Riewaldt, Julia ^a   Wehner, Rebekka ^b   Schmitz, Marc ^b,c   Odendahl, Marcus ^a   Bornhäuser, Martin ^c,d   Tonn, Torsten ^a,b,c  

^a Red Cross Donor Service Sachsen   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Gamma irradiation; GvHD; Immunosuppression; Mesenchymal stromal cells

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADULT; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CFU COUNTING; CYTOLOGY; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; MESENCHYMAL STROMA CELL; MIDDLE AGED; RADIATION RESPONSE; T LYMPHOCYTE; WESTERN BLOTTING; YOUNG ADULT;

ADULT; APOPTOSIS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; BONE MARROW; CELL DIFFERENTIATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84904722617     PISSN: 15821838     EISSN: 15824934     Source Type: Journal    
DOI: 10.1111/jcmm.12264     Document Type: Article

References (53)

1. Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant. 2012; 18: 822-40.
2. Frenette PS, Pinho S, Lucas D, et al. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 2013; 31: 285-316.
3. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant. 2012; 47: 164-71.
4. Tolar J, Le Blanc K, Keating A, et al. Concise Review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010; 28: 1446-55.
5. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012; 1266: 107-17.
6. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009; 373: 1550-61.
7. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012; 119: 296-307.
8. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. Milwaukee, WI: CIBMTR; 2011.
9. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013; 2: 25-32.
10. Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990; 76: 418-23.
11. Gallardo D, Garcia-Lopez J, Sureda A, et al. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Bone Marrow Transplant. 1997; 20: 945-52.
12. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007; 7: 340-52.
13. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991; 77: 1821-8.
14. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001; 97: 1196-201.
15. Martínez C, Urbano-Ispízua A. Graft-versus-host disease therapy: something else beyond glucocorticoids? Haematologica. 2011; 96: 1249-51.
16. Inamoto Y, Flowers MID. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011; 18: 414-20.
17. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013; 15: 2-8.
18. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363: 1439-41.
19. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390-7.
20. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579-86.
21. von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009; 43: 245-51.
22. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009; 15: 804-11.
23. Lucchini G, Introna M, Dander E, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010; 16: 1293-301.
24. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011; 17: 534-41.
25. Kramann R, Kunter U, Brandenburg VM, et al. Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. J Bone Miner Res. 2013; 28: 2523-34.
26. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007; 110: 1362-9.
27. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010; 12: 576-8.
28. Barkholt L, Flory E, Jekerle V, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies-Bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013; 15: 753-9.
29. Sensebe L, Gadelorge M, Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther. 2013; 4: 66.
30. Santos GW, Cole LJ. Effects of donor and host lymphoid and myeloid tissue injections in lethally x-irradiated mice treated with rat bone marrow. J Natl Cancer Inst. 1958; 21: 279-93.
31. Tyan ML. Modification of severe graft-versus-host disease with antisera to the (theta) antigen or to whole serum. Transplantation. 1973; 15: 601-4.
32. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966-1967; 62: 21-78.
33. Anderson KC. Clinical indications for blood component irradiation. In: Baldwin ML, Jefferies LC, editors. Irradiation of blood components. Bethesda: American Association of Blood Banks; 1992. pp. 31-49.
34. Li JKD, Chan GC. The effects of various irradiation doses on the growth and differentiation of marrow-derived human mesenchymal stromal cells. Pediatr Transplant. 2007; 11: 379-87.
35. Chen MF, Lin CT, Chen WC, et al. The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys. 2006; 66: 244-53.
36. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7: 393-5.
37. Pelszynski MM, Moroff G, Luban NLC, et al. Effect of gamma irradiation of red blood cell units on T-Cell Inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood. 1994; 83: 1683-9.
38. Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009; 43: 447-54.
39. Reed W, Lee TH, Norris PJ, et al. Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients. Semin Hematol. 2007; 44: 24-31.
40. Nelson JL. The otherness of self: microchimerism in health and disease. Trends Immunol. 2012; 33: 421-7.
41. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012; 30: 1575-8.
42. Meleshko A, Prakharenia I, Kletski S, et al. Chimerism of allogeneic mesenchymal cells in bone marrow, liver, and spleen after mesenchymal stem cells infusion. Pediatr Transplant. 2013; 17: E189-94.
43. Fouillard L, Bensidhoum M, Bories D, et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia. 2003; 17: 474-6.
44. Penn I. Tumors of the immunocompromised patient. Annu Rev Med. 1988; 39: 63-73.
45. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz, TFG). Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesammtnovelle 2005 mit Richtlinienanpassung 2010. Köln: Deutscher Ärtze-Verlag; 2010. pp. 41-3.
46. Filion TM, Qiao M, Ghule PN, et al. Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol. 2009; 220: 586-92.
47. Meijne EI, van der Winden-van Groenewegen RJ, Ploemacher RE, et al. The effects of x-irradiation on hematopoietic stem cell compartments in the mouse. Exp Hematol. 1991; 19: 617-23.
48. Harfouche G, Martin MT. Response of normal stem cells to ionizing radiation: a balance between homeostasis and genomic stability. Mutat Res. 2010; 704: 167-74.
49. Sotiropoulou PA, Candi A, Mascre G, et al. Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nat Cell Biol. 2010; 12: 572-82.
50. Tiberio R, Marconi A, Fila C, et al. Keratinocytes enriched for stem cells are protected from anoikis via an integrin signaling pathway in a Bcl-2 dependent manner. FEBS Lett. 2002; 524: 139-44.
51. Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radio-resistant members of the bone marrow. Immunol Cell Biol. 2013; 91: 5-11.
52. Cmielova J, Havelek R, Soukup T, et al. Gamma radiation induces senescence in human adult mesenchymal stem cells from bone marrow and periodontal ligaments. Int J Radiat Biol. 2012; 88: 393-404.
53. Damek-Poprawa M, Stefanik D, Levin LM, et al. Human bone marrow stromal cells display variable anatomic site-dependent response and recovery from irradiation. Arch Oral Biol. 2010; 55: 358-64.